F. Hoffmann-La Roche Ltd: European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered
non-inferior
7
Basel, 23 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo
, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.
F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered
What’s new in breast cancer research? SABCS20 goes virtual
Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more December 18, 2020 • By Diane Mapes / Fred Hutch News Service The 2020 San Antonio Breast Cancer Symposium, held virtually this year because of COVID-19, featured the latest research to inform the care of people with breast cancer. Getty Images stock photo
The San Antonio Breast Cancer Symposium was a virtual event this pandemic year, allowing thousands of breast cancer researchers, oncologists and patient advocates from around the world to log in for four full days of science and resilience writ large.
Dec 17, 2020
The annual meeting of the San Antonio Breast Cancer Symposium was held virtually this year from Dec. 8 to 11 and attracted participants from around the world, including medical oncologists, radiation oncologists, researchers, and other health care professionals. The conference highlighted recent advances in the risk, diagnosis, treatment, and prevention of breast cancer, with presentations focusing on emerging treatments in hard-to-treat patient populations, including patients with metastatic breast cancer.
As part of the RxPONDER study, Kevin Kalinsky, M.D., of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University in Atlanta, and colleagues found that postmenopausal women with lymph node-positive early-stage breast cancer and a low recurrence score receive no additional benefit from chemotherapy.
A Disappointment in Triple-Negative Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.